Thymosin fraction 5 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-08-05. Where a claim depends on a specific study, the study is described rather than over-claimed.
Thymosin alpha-1 is a synthetic peptide of 28 amino acid residues that corresponds to a naturally occurring fragment first isolated from thymus tissue. Its chain is acetylated at the amino terminus, a modification that shields the peptide from rapid cleavage by aminopeptidases. The molecule carries a net negative charge at physiological pH and dissolves freely in water. Researchers classify it as an immune-modulating agent rather than a classical hormone, because it acts on several cell types of both the innate and the adaptive immune system.
The peptide was identified during work in the 1970s on thymosin fraction 5, a partially purified extract of calf thymus. Investigators separated that mixture and characterized individual components, one of which they named thymosin alpha-1. The same compound later received the international nonproprietary name thymalfasin. Commercial material is produced by solid-phase peptide synthesis rather than by extraction, so synthetic and natural forms share an identical sequence. Naming conventions vary across the literature, and readers should distinguish the alpha-1 peptide from other thymosins that have unrelated sequences and functions.
Thymosin beta-4 is a separate 43-residue peptide that binds actin and participates in cell migration; it shares no sequence similarity with thymosin alpha-1 despite the common family name. Other preparative materials, such as thymosin fraction 5 and thymopoietin, contain distinct mixtures or peptides. The shared thymosin label reflects the tissue of origin used in early purification, not a common structural core. Treating these molecules as interchangeable is a frequent source of confusion in laboratory reports and in popular summaries alike.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | About 3.1 kDa | 28 residues, N-terminally acetylated |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Freely soluble in water | Also soluble in aqueous buffers |
| Storage temperature | 2 to 8 °C | Protect from light and moisture |
| Common synonyms | Thymalfasin; Tα1 | Same peptide sequence |
Clinical interest has centered on chronic viral hepatitis, on immune restoration in various conditions, and on use as an adjuvant intended to improve responses to vaccines. Trials have reported mixed results, and regulatory status differs sharply between countries; in some places it is a prescription product, while elsewhere it is sold without an approved therapeutic indication. Because published studies vary widely in design, population, and endpoints, comparisons across them are difficult and no single conclusion covers the whole literature.
Thymosin alpha 1 is a short peptide of 28 amino acid residues that derives from the amino terminal region of a larger precursor protein known as prothymosin alpha. The peptide carries an acetyl group on its first residue and contains no disulfide bonds or carbohydrate chains. Its sequence is highly conserved across mammalian species, which is one reason laboratories treat it as a molecule with a defined and reproducible structure rather than a variable tissue extract. The name follows an early naming convention for thymus-derived fractions and does not imply that the peptide acts as a hormone in the classical endocrine sense.
Biologically, the peptide is studied mainly in the context of immune cell development and regulation. It is produced in the thymus and in several other tissues, and it appears to influence the maturation and activity of T cells and other immune populations. Laboratory work describes effects on cytokine production, on the balance between T cell subsets, and on the function of dendritic cells. Much of this evidence comes from cell culture and animal models, so the extent to which the same pathways operate in humans remains an open question.
Within the immune system, the peptide acts on several cell types rather than a single target. Reported activities include promotion of T-cell maturation, enhancement of natural killer cell activity, and modulation of cytokine production by dendritic cells and macrophages. Some of these effects appear to operate through toll-like receptor signaling, though the precise receptor-level mechanism remains debated. Whether the observed immune changes translate into clinical benefit is a separate question and depends on the indication studied.
The peptide was described in the 1970s as a component of thymic extracts, and early research focused on restoring immune function in immunodeficiency states. A synthetic version entered clinical development in the 1980s and is approved as a drug in several countries for conditions such as chronic hepatitis B and certain immunodeficiencies. Approval status varies widely by jurisdiction, and in the United States it is not an approved therapeutic. Regulatory and clinical positions differ, so statements about efficacy should be tied to specific indications and studies.
The peptide is generated in cells by cleavage of prothymosin alpha, a larger acidic protein encoded by the PTMA gene. Prothymosin alpha is expressed in many tissues, not only in the thymus, and its functions include nuclear roles in chromatin-related processes. The 28-residue fragment corresponds to the N-terminal portion of that precursor. How the cleavage occurs and how the fragment's concentration is regulated remain open questions; circulating amounts are small and difficult to measure reliably with routine assays.
Thymosin alpha 1 is a short peptide first isolated from bovine thymus tissue in the early 1970s during fractionation work aimed at identifying factors that influence T cell development. It belongs to a family of acidic thymic peptides, and the original preparations contained several components that were later separated by chromatography. The compound is now produced synthetically rather than extracted from tissue, which removes batch variability tied to animal sourcing. Researchers describe it as an immunomodulatory peptide because laboratory studies show effects on several cell types of the innate and adaptive immune systems.
=== Stem cell biology === Synthetic retinoic acid is used in differentiation of stem cells to more committed fates, echoing retinoic acid's importance in natural embryonic developmental pathways. It is thought to initiate differentiation into several different cell lineages through activation of the Retinoic acid receptor. It has numerous applications in the experimental induction of stem cell differentiation; amongst these is the differentiation of human embryonic stem cells to posterior foregut lineages.
The three Western Allies retained occupation powers in Berlin and certain responsibilities for Germany as a whole. Under the new arrangements, the Allies stationed troops within West Germany for NATO defence, pursuant to stationing and status-of-forces agreements. With the exception of 55,000 French troops, Allied forces were under NATO's joint defence command. (France withdrew from the collective military command structure of NATO in 1966.)
2 Fe2O3 + 3 C → 4 Fe + 3 CO2 The flux removes silicaceous minerals in the ore, which would otherwise clog the furnace: The heat of the furnace decomposes the carbonates to calcium oxide, which reacts with any excess silica to form a slag composed of calcium silicate CaSiO3 or other products. At the furnace's temperature, the metal and the slag are both molten. They collect at the bottom as two immiscible liquid layers (with the slag on top), that are then easily separated. The slag can be used as a material in road construction or to improve mineral-poor soils for agriculture. Steelmaking thus remains one of the largest industrial contributors of CO2 emissions in the world.
Shock: Injury, Inflammation, and Sepsis: Laboratory and Clinical Approaches (ISSN 1073-2322) is the official journal of the Shock Society, the European Shock Society, the Indonesian Shock Society, the International Federation of Shock Societies, and the Official and International Journal of the Japan Shock Society. The journal publishes scholarly research reports on basic and clinical studies of shock, trauma, sepsis, inflammation, ischemia, and related pathobiological states, with particular emphasis on the biologic mechanisms that determine the response to such injury. This scholarly journal has both print and online version. The journal has an impact factor of 3.1 and publishes 12 issues per year.
Sources: en.wikipedia.org
Brian Niccol, chair and CEO of Starbucks Richard Allison, former CEO of Domino's Pizza Andrew Campion, COO of Nike, Inc. Beth Ford, CEO of Land O'Lakes Jørgen Vig Knudstorp, executive chairman of LEGO Group Marissa Mayer, former president and CEO of Yahoo! Neal Mohan, CEO of YouTube Dambisa Moyo, Co-principal of Versaca Investments Daniel Servitje, CEO of Grupo Bimbo Mike Sievert, former CEO of T-Mobile US Wei Zhang, former president of Alibaba Pictures Group Howard Schultz, president and former CEO of Starbucks
== Function == Gastrin-releasing peptide is a regulatory human peptide that elicits gastrin release and regulates gastric acid secretion and enteric motor function. The post-ganglionic fibers of the vagus nerve that innervate bombesin/GRP neurons of the stomach release GRP, which stimulates the G cells to release gastrin. GRP is also involved in the biology of the circadian system, playing a role in the signaling of light to the master circadian oscillator in the suprachiasmatic nuclei of the hypothalamus. Furthermore, GRP seems to mediate certain aspects of stress. This is the reason for the observed fact that atropine does not block the vagal effect on gastrin release.
Zinc pyrithione (or pyrithione zinc) is a coordination complex of zinc. It has fungistatic (inhibiting the division of fungal cells) and bacteriostatic (inhibiting bacterial cell division) properties and is used in the treatment of seborrhoeic dermatitis and dandruff.
Wingstop's menu includes a wide range of chicken products such as bone-in and boneless wings, chicken tenders, and fried chicken sandwiches. There are 13 wing sauces, with some sauces available for limited periods as part of marketing efforts. Sides include fries, fried corn, and veggie sticks (carrots and/or celery). Sauces include ranch, blue cheese, honey mustard, and cheese sauce. The menu also includes chocolate brownies as a dessert option.
=== Personal life and death === Dyson married his first wife, the Swiss mathematician Verena Huber, on 11 August 1950. They had two children, Esther and George, before divorcing in 1958. In November 1958 he married Imme Jung, with whom he had four daughters. Dyson died on 28 February 2020 at Penn Medicine Princeton Medical Center in Plainsboro Township, New Jersey, from complications following a fall. He was 96.
Sources: en.wikipedia.org
This research provided a new drug that could serve as a new treatment for amebiasis caused by the Entamoeba histolytica. In 2017, auranofin completed phase I clinical trials against Entamoeba histolytica and Giardia The Barrios Lab in the Department of Pharmacy at the University of Utah largely focuses on developing chemical probes to study biological substrates, substrate selectivity, cellular regulation, and druggability for use in therapeutics. Human protein tyrosine phosphatases (PTPs) hold substantial relevance in human autoimmunity and T-cell receptor signaling, as well as cell signaling in diseases. Novel chemical probes to better understand the activity and regulation of this family of enzymes aids in developing human therapeutics. These developments in the Barrios Lab include fluorogenic probes to investigate PTP activity, along with profiling substrate selectivity for the use of developing potent, selective inhibitors. Additionally, the Barrios Lab also focuses on chemical tools used to study the therapeutic roles of metal ions as biological targets of gold-based compounds.
== Career == Beginning in the late 1970s, at Columbia University, Wigler, Richard Axel and Saul Silverstein developed methods for engineering animal cells. These methods are the basis for many discoveries in mammalian genetics, and the means for producing protein therapeutics such as those used to treat heart disease, cancer and strokes. After moving to CSHL, Wigler continued his studies of gene transfer into mammalian cells, exploring the integration of foreign DNA and its stability of expression in host cells, demonstrating the inheritance of DNA methylation patterns, and isolating the first vertebrate genes, and first human oncogenes, using DNA transfer and genetic selection. His laboratory was among the group that first showed the involvement of members of the RAS gene family in human cancer, and that point mutations can activate the oncogenic potential of cellular genes. Wigler's laboratory was the first to demonstrate that some regulatory pathways have been so conserved in evolution that yeast can be used as a host to study the function of mammalian genes and in particular genes involved in signal transduction pathways and cancer. This led to deep insights into RAS function, eventually solving the RAS biochemical pathway in yeast and humans, and demonstrating the multifunctional nature of this important oncogene. From this work in fungi new cellular mechanisms were recognized for "insulating" signal transduction pathways with protein scaffolds that reduce cross-talk and for processing and localization of proteins.
I do not support Hamas." Kennedy repeated the same questions, and Berry responded, "The introduction of foreign policy is not how we keep Arab Americans or Jewish Americans or Muslim Americans or Black people or Asian Americans—anybody—safe. This has been regrettably a real disappointment but very much an indication of the danger to our democratic institutions that we're in now." Kennedy's concluding remark to Berry was "You should hide your head in a bag." Kennedy's words drew backlash from political figures, including Dick Durbin. In September, Kennedy helped secure an extension of the National Flood Insurance Program before Hurricanes Helene and Milton. Without the extension, funding for the flood insurance program would have lapsed on September 30.
The traditional account exaggerates the importance of Fulton and Jacobsen to Moniz's decision to initiate frontal lobe surgery, and omits the fact that a detailed body of neurological research that emerged at this time suggested to Moniz and other neurologists and neurosurgeons that surgery on this part of the brain might yield significant personality changes in the mentally ill. The frontal lobes have been the object of scientific inquiry and speculation since the late 19th century. Fulton's contribution, while it may have functioned as a source of intellectual support, is in itself unnecessary and inadequate as an explanation of Moniz's resolution to operate on this section of the brain. Under an evolutionary and hierarchical model of brain development, it had been hypothesized that those regions associated with the more recent development, such as the mammalian brain and, most especially, the frontal lobes, were responsible for more complex cognitive functions. However, this theoretical formulation found little laboratory support, as 19th-century experimentation found no significant change in animal behaviour following surgical removal or electrical stimulation of the frontal lobes. This picture of the so-called "silent lobe" changed in the period after World War I with the production of clinical reports of ex-servicemen with brain trauma. The refinement of neurosurgical techniques also facilitated increasing attempts to remove brain tumours and treat focal epilepsy in humans, and led to more precise experimental neurosurgery in animal studies.
Sources: en.wikipedia.org
It is a 28-residue synthetic peptide studied as an immune-modulating agent and approved as a drug in some countries. The sequence matches a naturally occurring fragment isolated from thymus tissue. It is not a hormone in the endocrine sense.
The name traces back to thymosin fraction 5, a crude thymus extract examined in the 1970s. Individual peptides in that mixture were labeled with Greek letters, and alpha-1 was one of them. The international nonproprietary name thymalfasin was assigned later.
No. Thymosin beta-4 contains 43 residues and binds actin, while thymosin alpha-1 contains 28 residues and acts on immune cells. The two sit in a historical naming group but share no sequence similarity, and they are not substitutes for one another.
Trials differ in patient population, dose schedule, background treatment, and the endpoints used to judge success. Many are small and single-center, so random variation can dominate the reported effects.